BioLargo, Aquatech Unite on PFAS Treatment Push

BioLargo and Aquatech sign an MOU to combine AEC concentration tech with large-scale PFAS removal systems for global municipal and industrial clients.

23 Jun 2026

Two cleantech companies have agreed to combine their water treatment technologies in a partnership aimed at one of the most persistent contamination problems facing utilities worldwide. BioLargo and Aquatech signed a memorandum of understanding on May 4, 2026, integrating BioLargo's Aqueous Electrostatic Concentrator technology into Aquatech's established PFAS removal and destruction systems. The collaboration targets municipal and industrial clients across the United States and the Asia Pacific region, where regulators have grown increasingly assertive about drinking water standards.

PFAS compounds, sometimes called forever chemicals for their resistance to natural breakdown, have placed mounting pressure on water utilities and government agencies for years. BioLargo's AEC technology captures and concentrates the chemicals with precision; Aquatech contributes large-scale purification infrastructure capable of moving solutions from pilot programs to full deployment. Neither company could bridge that gap as efficiently working alone, analysts said, and the timing carries added weight as global compliance frameworks continue to tighten.

Devesh Mittal, Vice President of Aquatech Environmental Services, described the strategic rationale directly. "Coupling BioLargo's AEC PFAS collection and concentration technology with Aquatech's PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions," he said. Communities facing regulatory deadlines on drinking water safety stand to benefit most from an arrangement structured to compress development timelines.

For industrial operators, the agreement offers an integrated pathway in which concentration and destruction no longer require separate vendor relationships. Municipal water authorities may find particular value in end-to-end treatment systems that are both technically rigorous and commercially viable at scale. Asia Pacific markets could prove especially consequential, given the pace at which new compliance requirements are being adopted across that region.

Positioned at the intersection of regulatory pressure and commercial opportunity, both organizations now hold a credible foundation from which to pursue major contracts across multiple geographies. The results of their combined deployments could shape procurement decisions and policy benchmarks in the years ahead.